9月10日 - ** 制药商Soleno Therapeutics SLNO.O股价下跌12%，至61.15美元
** 该公司称， (link)，一名患有普拉德-威利综合征和多种健康问题的17岁患者在服用Vykat XR时死于肺栓塞，肺栓塞是一种因血栓阻塞肺部血流而导致的疾病。
** 主治医生和Soleno公司表示，患者的死亡与其罕见的遗传疾病药物无关。
** 上个月， (link)，Scorpion Capital称，由于Vykat XR存在问题，该公司已对Soleno公司采取了空头立场。
** 3月， (link)，FDA批准Vykat XR用于治疗一种名为Prader-Willi综合症的罕见遗传疾病。
** 包括本交易日的走势在内，该股今年累计上涨 36
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.